A detailed history of Moore Capital Management, LP transactions in Argenx Se stock. As of the latest transaction made, Moore Capital Management, LP holds 22,000 shares of ARGX stock, worth $13.1 Million. This represents 0.25% of its overall portfolio holdings.

Number of Shares
22,000
Previous 25,000 12.0%
Holding current value
$13.1 Million
Previous $10.8 Million 10.98%
% of portfolio
0.25%
Previous 0.2%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$434.22 - $551.9 $1.3 Million - $1.66 Million
-3,000 Reduced 12.0%
22,000 $11.9 Million
Q2 2024

Aug 14, 2024

SELL
$356.01 - $451.55 $1.78 Million - $2.26 Million
-5,000 Reduced 16.67%
25,000 $10.8 Million
Q1 2024

May 15, 2024

BUY
$356.95 - $413.29 $1.78 Million - $2.07 Million
5,000 Added 20.0%
30,000 $11.8 Million
Q4 2023

Feb 14, 2024

BUY
$338.91 - $506.01 $3.05 Million - $4.55 Million
9,000 Added 56.25%
25,000 $9.51 Million
Q3 2023

Nov 14, 2023

BUY
$369.35 - $548.43 $2.22 Million - $3.29 Million
6,000 Added 60.0%
16,000 $7.87 Million
Q2 2023

Aug 14, 2023

BUY
$360.14 - $422.58 $3.6 Million - $4.23 Million
10,000 New
10,000 $3.9 Million
Q3 2022

Nov 14, 2022

SELL
$343.2 - $395.75 $2.82 Million - $3.25 Million
-8,209 Reduced 47.71%
8,998 $3.18 Million
Q2 2022

Aug 15, 2022

BUY
$269.58 - $378.88 $4.64 Million - $6.52 Million
17,207 New
17,207 $6.52 Million
Q1 2022

May 16, 2022

SELL
$254.45 - $351.06 $2.92 Million - $4.03 Million
-11,471 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$272.01 - $353.03 $3.12 Million - $4.05 Million
11,471 New
11,471 $4.02 Million
Q4 2018

Feb 14, 2019

SELL
$63.81 - $109.82 $1.28 Million - $2.2 Million
-20,000 Closed
0 $0
Q3 2018

Nov 14, 2018

BUY
$75.5 - $96.63 $1.51 Million - $1.93 Million
20,000 New
20,000 $1.52 Million

Others Institutions Holding ARGX

About ARGENX SE


  • Ticker ARGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,323,800
  • Market Cap $32.9B
  • Description
  • argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...
More about ARGX
Track This Portfolio

Track Moore Capital Management, LP Portfolio

Follow Moore Capital Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Moore Capital Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Moore Capital Management, LP with notifications on news.